• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于HIV感染暴露前预防试验的药物标准。

Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.

作者信息

Derdelinckx Inge, Wainberg Mark A, Lange Joep M A, Hill Andrew, Halima Yasmin, Boucher Charles A B

机构信息

University Medical Center, Eijkman Winkler Institute, Department of Virology, Utrecht, Netherlands.

出版信息

PLoS Med. 2006 Nov;3(11):e454. doi: 10.1371/journal.pmed.0030454.

DOI:10.1371/journal.pmed.0030454
PMID:17090213
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1630715/
Abstract

The authors formulate criteria for an optimal pre-exposure prophylaxis drug candidate, and evaluate existing antiviral drug classes for their suitability.

摘要

作者制定了最佳暴露前预防药物候选物的标准，并评估了现有抗病毒药物类别是否合适。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/1664606/887de4de838c/pmed.0030454-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/1664606/72ccfb66c9a1/pmed.0030454-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/1664606/887de4de838c/pmed.0030454-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/1664606/72ccfb66c9a1/pmed.0030454-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8f88/1664606/887de4de838c/pmed.0030454-g002.jpg

相似文献

1
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.用于HIV感染暴露前预防试验的药物标准。
PLoS Med. 2006 Nov;3(11):e454. doi: 10.1371/journal.pmed.0030454.
2
Silver bullets and structural impediments to HIV prevention.预防艾滋病的良方与结构障碍
Lancet HIV. 2019 Nov;6(11):e729-e732. doi: 10.1016/S2352-3018(19)30274-7. Epub 2019 Aug 23.
3
HIV study yields unexpected preliminary efficacy results.艾滋病病毒研究得出了意外的初步疗效结果。
Am J Health Syst Pharm. 2008 Apr 15;65(8):686-8. doi: 10.2146/news080031.
4
Efficacy and cost-effectiveness of early antiretroviral therapy and partners' pre-exposure prophylaxis among men who have sex with men in Shenyang, China: a prospective cohort and costing study.中国沈阳男男性行为者中早期抗逆转录病毒治疗和伴侣暴露前预防的疗效和成本效益：一项前瞻性队列和成本研究。
BMC Infect Dis. 2019 Jul 25;19(1):663. doi: 10.1186/s12879-019-4275-x.
5
First Extended-Release Injectable Drug Therapy for HIV.首个长效注射抗 HIV 药物。
Am J Nurs. 2021 May 1;121(5):24-25. doi: 10.1097/01.NAJ.0000751096.82989.00.
6
How many MSM in Europe could benefit from PrEP--a 9 billion Euro question?在欧洲有多少男男性行为者能从暴露前预防中受益——这是个价值90亿欧元的问题？
Int J STD AIDS. 2015 Nov;26(13):988-90. doi: 10.1177/0956462415584490.
7
[Should pre-exposure prophylaxis be used to prevent HIV?].[暴露前预防是否应用于预防艾滋病毒？]
Rev Med Suisse. 2015 Mar 11;11(465):622-3.
8
Learning and doing: operational research and access to HIV treatment in Africa.学习与实践：非洲的运筹学与艾滋病治疗获取情况
AIDS. 2010 Jan;24 Suppl 1:S1-4. doi: 10.1097/01.aids.0000366077.37827.0a.
9
Assessing the cost effectiveness of pre-exposure prophylaxis for HIV prevention in the US.评估美国 HIV 预防暴露前预防的成本效益。
Pharmacoeconomics. 2013 Dec;31(12):1091-104. doi: 10.1007/s40273-013-0111-0.
10
[Pre-exposure prophylaxis and selection of HIV resistant strains: Attention should be paid to the pre-exposure prophylaxis initiated during the seronegative initial period of HIV primary infection ].暴露前预防与HIV耐药毒株的选择：应关注在HIV初次感染血清阴性初期启动的暴露前预防。
Med Mal Infect. 2015 Aug;45(8):341-2. doi: 10.1016/j.medmal.2015.06.004. Epub 2015 Aug 8.

引用本文的文献

1
Considerations for capsid-targeting antiretrovirals in pre-exposure prophylaxis.暴露前预防中衣壳靶向抗逆转录病毒药物的考量因素。
Trends Mol Med. 2025 Feb 27. doi: 10.1016/j.molmed.2025.01.013.
2
Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.拉米夫定/替诺福韦酯富马酸是一种合适的暴露前预防方案。
Drugs. 2020 Dec;80(18):1881-1888. doi: 10.1007/s40265-020-01419-4.
3
Pre-exposure Prophylaxis for HIV Infection in the Older Patient: What can be Recommended?老年患者HIV感染的暴露前预防：有哪些可推荐的措施？

本文引用的文献

1
Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study.在坦桑尼亚达累斯萨拉姆通过用拉米夫定对婴儿进行预防性治疗来预防HIV-1母婴传播：米特拉研究
J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):315-23. doi: 10.1097/QAI.0b013e31816e395c.
2
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.通过每日或间歇性使用恩曲他滨和替诺福韦预防猕猴直肠感染猴-人免疫缺陷病毒。
PLoS Med. 2008 Feb;5(2):e28. doi: 10.1371/journal.pmed.0050028.
3
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.
Drugs Aging. 2018 Jun;35(6):485-491. doi: 10.1007/s40266-018-0553-3.
4
Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.C5A对人源化小鼠阴道和直肠HIV攻击的保护效力
Open Virol J. 2018 Feb 28;12:1-13. doi: 10.2174/1874357901812010001. eCollection 2018.
5
Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.验证一种 LC-MS/MS 测定法，以同时监测干血斑中替诺福韦、恩曲他滨和拉米夫定的细胞内活性代谢物。
J Pharm Biomed Anal. 2018 Feb 5;149:40-45. doi: 10.1016/j.jpba.2017.10.030. Epub 2017 Oct 31.
6
Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.在人源化小鼠中通过抗逆转录病毒联合用药预防阴道和直肠HIV传播。
PLoS One. 2017 Sep 7;12(9):e0184303. doi: 10.1371/journal.pone.0184303. eCollection 2017.
7
Tribute to Mark Wainberg.向马克·温伯格致敬。
Retrovirology. 2017 Jun 28;14(1):38. doi: 10.1186/s12977-017-0361-6.
8
Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns.用于预防艾滋病病毒的暴露前预防：安全性问题。
Drug Saf. 2017 Apr;40(4):273-283. doi: 10.1007/s40264-017-0505-6.
9
Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.以区室特异性方式激活替诺福韦的激酶遗传变异体的发现。
EBioMedicine. 2015 Jul 9;2(9):1145-52. doi: 10.1016/j.ebiom.2015.07.008. eCollection 2015 Sep.
10
Role of the pharmacist in pre-exposure chemoprophylaxis (PrEP) therapy for HIV prevention.药剂师在用于预防HIV的暴露前化学预防（PrEP）治疗中的作用。
Pharm Pract (Granada). 2009 Jan;7(1):11-8. doi: 10.4321/s1886-36552009000100002. Epub 2009 Mar 15.
HIV-1 C亚型病毒在细胞培养中对替诺福韦迅速产生K65R耐药性。
AIDS. 2006 Jun 12;20(9):F9-13. doi: 10.1097/01.aids.0000232228.88511.0b.
4
Has global HIV incidence peaked?全球艾滋病病毒感染率已达峰值吗？
Lancet. 2006 Apr 8;367(9517):1120-2. doi: 10.1016/S0140-6736(06)68436-5.
5
Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection.预防艾滋病毒传播的杀微生物剂：克服化学屏障保护面临的障碍
J Infect Dis. 2006 Jan 1;193(1):36-44. doi: 10.1086/499163. Epub 2005 Nov 17.
6
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor.口服递送的CCR5抑制剂对猕猴阴道感染SHIV的保护作用。
Nat Med. 2005 Dec;11(12):1293-4. doi: 10.1038/nm1321. Epub 2005 Nov 6.
7
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.男性包皮环切术降低HIV感染风险的随机对照干预试验：ANRS 1265试验
PLoS Med. 2005 Nov;2(11):e298. doi: 10.1371/journal.pmed.0020298. Epub 2005 Oct 25.
8
Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus.猿猴免疫缺陷病毒经阴道传播后的感染传播与扩散
J Virol. 2005 Jul;79(14):9217-27. doi: 10.1128/JVI.79.14.9217-9227.2005.
9
The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.HIV-1逆转录酶中M184V突变对含或不含去羟肌苷的高效抗逆转录病毒治疗方案病毒学结果的影响。
Antivir Ther. 2005;10(2):357-61.
10
Clinically relevant genotype interpretation of resistance to didanosine.对去羟肌苷耐药的临床相关基因型解读。
Antimicrob Agents Chemother. 2005 May;49(5):1739-44. doi: 10.1128/AAC.49.5.1739-1744.2005.